Beneficial effects of transdermal administration of tamoxifen on capsular contracture after breast implantation in murine models.
Breast reconstruction
Capsule contracture
Silicone implant
Tamoxifen
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
24
05
2021
accepted:
23
11
2021
pubmed:
21
1
2022
medline:
3
3
2022
entrez:
20
1
2022
Statut:
ppublish
Résumé
Capsular contracture is the most common complication with smooth-type silicone implants. We investigated the preventive effect of an active metabolite of tamoxifen, 4-hydroxytamoxifen (4-OH TAM), on capsular contracture. A silicone sheet was implanted into the back of 28 female ICR mice. Mixtures of gel with 0.2% 4-OH TAM and 0.1% 4-OH TAM were administered transdermally once a day for 4 weeks. Saline was administered to the control. After killing the mice, capsular thickness was measured in H&E-stained specimens. Estrogen receptor (ER), α-smooth muscle actin (α-SMA), and transforming growth factor-β (TGF-β) expressions were immunohistochemically investigated in the capsules. The capsule was thinner in the 0.2% 4-OH TAM gel group than in the control group (control, 0.1% 4-OH TAM gel, 0.2% 4-OH TAM gel: 52.8 ± 3.4 µm, 54.2 ± 6.8 µm, 46.4 ± 3.3 µm, respectively). ER was found in most fibroblasts of all samples. α-SMA expression in the capsule was significantly lower in the 4-OH TAM gel groups than in the control group (control = 70.0 ± 3.4%, 0.1% 4-OH TAM = 57.0 ± 3.4%, 0.2% 4-OH TAM = 49.4 ± 4.9%). TGF-β expression was significantly reduced by the 4-OH TAM gel injections dose-dependently (control = 67.3 ± 2.2%, 0.1% 4-OH TAM = 52.4 ± 3.1%, 0.2% 4-OH TAM = 45.1 ± 2.4%). The transdermal administration of 0.1% and 0.2% 4-OH TAM gels inhibited capsule development. The inhibition of TGF-β expression is a mechanism by which 4-OH TAM suppresses fibroblast growth, preventing capsular formation.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Capsular contracture is the most common complication with smooth-type silicone implants. We investigated the preventive effect of an active metabolite of tamoxifen, 4-hydroxytamoxifen (4-OH TAM), on capsular contracture.
METHODS
METHODS
A silicone sheet was implanted into the back of 28 female ICR mice. Mixtures of gel with 0.2% 4-OH TAM and 0.1% 4-OH TAM were administered transdermally once a day for 4 weeks. Saline was administered to the control. After killing the mice, capsular thickness was measured in H&E-stained specimens. Estrogen receptor (ER), α-smooth muscle actin (α-SMA), and transforming growth factor-β (TGF-β) expressions were immunohistochemically investigated in the capsules.
RESULTS
RESULTS
The capsule was thinner in the 0.2% 4-OH TAM gel group than in the control group (control, 0.1% 4-OH TAM gel, 0.2% 4-OH TAM gel: 52.8 ± 3.4 µm, 54.2 ± 6.8 µm, 46.4 ± 3.3 µm, respectively). ER was found in most fibroblasts of all samples. α-SMA expression in the capsule was significantly lower in the 4-OH TAM gel groups than in the control group (control = 70.0 ± 3.4%, 0.1% 4-OH TAM = 57.0 ± 3.4%, 0.2% 4-OH TAM = 49.4 ± 4.9%). TGF-β expression was significantly reduced by the 4-OH TAM gel injections dose-dependently (control = 67.3 ± 2.2%, 0.1% 4-OH TAM = 52.4 ± 3.1%, 0.2% 4-OH TAM = 45.1 ± 2.4%).
CONCLUSIONS
CONCLUSIONS
The transdermal administration of 0.1% and 0.2% 4-OH TAM gels inhibited capsule development. The inhibition of TGF-β expression is a mechanism by which 4-OH TAM suppresses fibroblast growth, preventing capsular formation.
Identifiants
pubmed: 35050493
doi: 10.1007/s12282-021-01316-y
pii: 10.1007/s12282-021-01316-y
doi:
Substances chimiques
Silicone Gels
0
Tamoxifen
094ZI81Y45
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
343-351Informations de copyright
© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.
Références
Barnsley GP, Sigurdson LJ, Barnsley SE. Textured surface breast implants in the prevention of capsular contracture among breast augmentation patients: a meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2006;117:2182–90.
doi: 10.1097/01.prs.0000218184.47372.d5
Calobrace MB, Stevens WG, Capizzi PJ, Cohen R, Godinez T, Beckstrand M. Risk factor analysis for capsular contracture: a 10-year sientra study using round, smooth, and textured implants for breast augmentation. Plast Reconstr Surg. 2018;141:20S-28S.
doi: 10.1097/PRS.0000000000004351
Keech JA, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 1997;100:554–5.
doi: 10.1097/00006534-199708000-00065
Cordeiro PG, Ghione P, Ni A, Hu Q, Ganesan N, Galasso N, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthetic Surg. 2020;73:841–6.
doi: 10.1016/j.bjps.2019.11.064
Headon H, Kasem A, Mokbel K. Capsular contracture after breast augmentation: an update for clinical practice. Arch Plast Surg. 2015;42:532–43.
doi: 10.5999/aps.2015.42.5.532
Siggelkow W, Faridi A, Spiritus K, Klinge U, Rath W, Klosterhalfen B. Histological analysis of silicone breast implant capsules and correlation with capsular contracture. Biomaterials. 2003;24:1101–9.
doi: 10.1016/S0142-9612(02)00429-5
Dolores W, Christian R, Harald N, Hildegunde P, Georg W. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on local immune reactions. J Autoimmun Academic Press. 2004;23:81–91.
doi: 10.1016/j.jaut.2004.03.005
Persichetti P, Segreto F, Carotti S, Marangi GF, Tosi D, Morini S. Oestrogen receptor-alpha and -beta expression in breast implant capsules: experimental findings and clinical correlates. J Plast Reconstr Aesthetic Surg. 2014;67:308–15.
doi: 10.1016/j.bjps.2013.12.002
Kim D, Sin Lee A, Jin Jung Y, Hee Yang K, Lee S, Kwang Park S, et al. Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor α-mediated transforming growth factor-β1/Smad signaling pathway. Nephrol Dial Transpl. 2014;29:2043–53.
doi: 10.1093/ndt/gfu240
Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, et al. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast. Clin Cancer Res. 2014;20:3672–82.
doi: 10.1158/1078-0432.CCR-13-3045
Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, et al. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol. 2005;23:2980–7.
doi: 10.1200/JCO.2005.06.064
Lin AJ, Karinja SJ, Bernstein JL, Jin J, Toyoda Y, Miller AJ, et al. In search of a murine model of radiation-induced periprosthetic capsular fibrosis. Ann Plast Surg NLM (Medline). 2018;80:S204–10.
doi: 10.1097/SAP.0000000000001362
Frenkiel BA, Temple-Smith P, de Kretser D, Southwick GJ. Follistatin and the breast implant capsule. Plast Reconstr Surg Glob Open. 2017;5:e1258.
doi: 10.1097/GOX.0000000000001258
Anderson EE, Perilli E, Carati CJ, Reynolds KJ. Quantifying shape changes of silicone breast implants in a murine model using in vivo micro-CT. J Biomed Mater Res Part B Appl Biomater. 2017;105:1447–52.
doi: 10.1002/jbm.b.33682
Lee SD, Yi MH, Kim DW, Lee Y, Choi Y, Oh SH. The effect of botulinum neurotoxin type A on capsule formation around silicone implants: the in vivo and in vitro study. Int Wound J. 2016;13:65–71.
doi: 10.1111/iwj.12228
Mehrvarz S, Ebrahimi A, Sahraei H, Bagheri MH, Fazili S, Manoochehry S, et al. Effects of topical tamoxifen on wound healing of burned skin in rats. Arch Plast Surg. 2017;44:378–83.
doi: 10.5999/aps.2017.44.5.378
Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011;121:3981–90.
doi: 10.1172/JCI57301
Park S, Park M, Kim BH, Lee JE, Park HJ, Lee SH, et al. Acute suppression of TGF-ß with local, sustained release of tranilast against the formation of fibrous capsules around silicone implants. J Control Release. 2015;200:125–37.
doi: 10.1016/j.jconrel.2014.12.021
Schlesinger SL, Ellenbogen R, Desvigne MN, Svehlak S, Heck R. Zafirlukast: a new treatment for capsular contracture. Aesthetic Surg J. 2002;22:329–36.
doi: 10.1067/maj.2002.126753
Kang SH, Shin KC, Kim WS, Bae TH, Kim HK, Kim MK. The preventive effect of topical zafirlukast instillation for peri-implant capsule formation in rabbits. Arch Plast Surg. 2015;42:179–85.
doi: 10.5999/aps.2015.42.2.179
Lee O, Ivancic D, Allu S, Shidfar A, Kenney K, Helenowski I, et al. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: Preclinical and clinical evaluation. Cancer Chemother Pharmacol. 2015;76:1235–46.
doi: 10.1007/s00280-015-2848-y
Ulrich D, Lichtenegger F, Eblenkamp M, Repper D, Pallua N. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants. Plast Reconstr Surg. 2004;114:229–36.
doi: 10.1097/01.PRS.0000129079.19089.6C
Tan KT, Wijeratne D, Shih B, Baildam AD, Bayat A. Tumour necrosis factor-α expression is associated with increased severity of periprosthetic breast capsular contracture. Eur Surg Res. 2010;45:327–32.
doi: 10.1159/000321009